News from csl behring A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 04, 2019, 09:33 ET CSL Behring Extends Support of World Federation of Hemophilia Programs

The World Federation of Hemophilia (WFH) and global biotherapeutics leader CSL Behring today announced that the company has renewed its commitment as a Visionary Corporate Partner with WFH for...


Mar 23, 2018, 09:55 ET CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors

CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II) clinical trial and the first patient enrollment. The...


Aug 09, 2017, 08:00 ET Berinert® Approved by Health Canada for the Treatment of Hereditary Angioedema (HAE) in Pediatric Patients

CSL Behring is pleased to announce that on March 31st, 2017 Berinert (C1 Esterase Inhibitor, Human) was approved by Heath Canada for Pediatric Hereditary Angioedema (HAE). "HAE is an unpredictable...


Apr 04, 2017, 08:00 ET New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients

Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the...


Dec 14, 2016, 13:58 ET Health Canada Approves CSL Behring's AFSTYLA™ for the Treatment of Hemophilia A

Global biotherapeutics leader CSL Behring announced that Health Canada has approved AFSTYLA [Antihemophilic Factor VIII (Recombinant), SingleChain], its novel long-lasting recombinant factor VIII...


Jun 24, 2015, 17:16 ET CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

CSL Behring today presented data from Phase III studies evaluating the efficacy and long-term safety of its investigational long-acting fusion protein linking recombinant coagulation factor IX with...


Jun 24, 2015, 08:31 ET CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single chain (rVIII-SingleChain) in adolescents and adults...


Jun 16, 2015, 09:00 ET CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

CSL Behring announced today it will present more than 20 abstracts, including five oral presentations, from across its hematology portfolio of investigational and branded products at the 2015...


May 15, 2015, 16:38 ET New and Convenient Vial Size of CSL Behring's Berinert® approved by Health Canada for the Treatment of Hereditary Angioedema

CSL Behring announced today that Health Canada has approved a new, low-volume presentation size for the existing indications of Berinert®, a human plasma-derived, pasteurized and nanofiltered...


May 15, 2015, 09:00 ET New and Convenient Vial Size of CSL Behring's Berinert® approved by Health Canada for the Treatment of Hereditary Angioedema

CSL Behring announced today that Health Canada has approved a new, low-volume presentation size for the existing indications of Berinert®, a human plasma-derived, pasteurized and nanofiltered...


Apr 23, 2015, 09:07 ET CSL Behring Awards Young Researchers Around the World to Advance Coagulation Science

CSL Behring announced today that the company has named five recipients of the 2015 CSL Behring Professor Heimburger Award for coagulation research. Now in its eighth year, the global awards program...


Apr 14, 2015, 09:30 ET CSL Behring Marks World Hemophilia Day by Renewing Pledge to World Federation of Hemophilia

In recognition of World Hemophilia Day April 17, the World Federation of Hemophilia (WFH) and CSL Behring announced today that CSL Behring has once again committed to donating bleeding disorder...


Mar 30, 2015, 08:58 ET European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients

CSL Behring announced today that the European Medicines Agency (EMA) has started the Centralized Procedure for reviewing the company's Marketing Authorization Application (MAA) for its long-acting...


Feb 04, 2015, 11:00 ET U.S. FDA Accepts for Review CSL Behring's Biologics License Application for rIX-FP for Hemophilia B Patients

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the marketing authorization of its long-acting fusion...


Dec 16, 2014, 09:04 ET CSL Behring Submits Biologics License Application for FDA Approval of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant Albumin (rIX-FP) for Hemophilia B Patients

CSL Behring announced today it has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the marketing authorization of its long-acting fusion...


May 14, 2014, 08:30 ET CSL Behring Proudly Supports HAE Day with Global Partnerships, Donations and Hereditary Angioedema Awareness Events

Third annual awareness day shines a light on rare, potentially life-threatening condition KING OF PRUSSIA, Pa., May 14, 2014 /CNW/ - As a Diamond Sponsor of HAE Day on May 16, 2014, CSL Behring is...


Sep 27, 2013, 01:04 ET CSL Behring Gains Approval to License Hizentra® in Japan for the Treatment of Primary Immunodeficiency and Secondary Immunodeficiency

TOKYO, Sept. 27, 2013 /CNW/ - CSL Behring announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Hizentra® (Immune Globulin Subcutaneous [Human]) for the...


Jun 04, 2013, 09:01 ET CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A

Results of Part 1 of the study will be presented at the 2013 International Society on Thrombosis and Haemostasis in Amsterdam, Netherlands on 2 July, 2013 KING OF PRUSSIA, Pa., June 4, 2013 /CNW/ -...


Oct 04, 2012, 04:01 ET New Model Compares Economic Value of Subcutaneous Immunoglobulin Therapy with Intravenous Immunoglobulin

Data presented at biennial ESID meeting reveal pharmacoeconomic benefits of switching from IVIG to SCIg in primary immunodeficiency FLORENCE, Italy, Oct. 4, 2012 /CNW/ - Analysis using a new economic ...


Oct 04, 2012, 04:01 ET Study Supports Efficacy, Safety of Hizentra® in Japanese Patients with Primary Immunodeficiency Disease

Subcutaneous therapy maintains high serum immunoglobulin levels, provides passive immunity and improves quality of life following conversion from intravenous treatment FLORENCE, Italy, Oct. 4, 2012...


Sep 07, 2012, 07:01 ET Avery-Landsteiner Prize for Immunology Awarded to Alain Fischer of Paris, France, by German Society for Immunology

GLASGOW, Scotland, Sept. 7, 2012 /CNW/ - The German Society for Immunology (DGfI) has awarded its 2012 Avery-Landsteiner Prize to Alain Fischer, M.D., Ph.D., of Paris, France, for his milestone...


Jul 11, 2012, 15:01 ET World's First Intensive Study of Postpartum Women with von Willebrand Disease Shows Potential Risk of Delayed Hemorrhage, Despite Treatment

Current VWD treatment strategies found potentially insufficient in postpartum period; further study of benefits of prophylaxis treatment needed KING OF PRUSSIA, Pa., July 11, 2012 /CNW/ - Findings of ...


May 03, 2012, 15:39 ET CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema

Phase I/II study to establish safety and clinical pharmacology with various doses of subcutaneous formulation of human C1-esterase inhibitor KING OF PRUSSIA, Pa. and MARBURG, Germany, May 3, 2012...


Apr 16, 2012, 16:06 ET CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period

Commitment will help WFH's "Close the Gap" campaign aimed at improving healthcare in developing world KING OF PRUSSIA, Pa. and MONTREAL, April 16, 2012 /CNW/ - To mark World Hemophilia Day 2012, CSL...


Mar 26, 2012, 10:51 ET First Patient Enrolled in CSL Behring PATH Trial to Evaluate Immune Globulin Subcutaneous (Human) 20% Liquid, Hizentra®, in the Treatment of CIDP

CHARLOTTE, N.C., March 26, 2012 /CNW/ - CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy,...